STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access ...
GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and ...
Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests GeneDx (Nasdaq: WGS), a ...
Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, announced its support for the Genomic Answers for Children’s Health Act. This legislation, introduced in the ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...
GeneDx reported full-year 2025 revenue of approximately $427M, inline with consensus of $427M, representing a 41% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback